Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Ligand polypeptide and drug delivery system specifically binding to mdscs

A delivery system and specific technology, applied in the field of protein peptides, can solve the problems of the complexity of immune regulation network, unsatisfactory treatment effect, etc., and achieve the effect of good gene silencing effect, good binding effect and good binding effect.

Active Publication Date: 2016-06-01
SHANGHAI JIAO TONG UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Unfortunately, due to the heterogeneity of MDSCs itself and the complexity of the immune regulatory network, the above methods have not achieved satisfactory therapeutic effects, so an in-depth understanding of the occurrence and development of MDSCs is very necessary to completely reverse the immunosuppressive activity of MDSCs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ligand polypeptide and drug delivery system specifically binding to mdscs
  • Ligand polypeptide and drug delivery system specifically binding to mdscs
  • Ligand polypeptide and drug delivery system specifically binding to mdscs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Example 1. In vivo phage screening technology to screen MDSCs targeting ligand candidate polypeptides

[0047] The in vivo phage screening technique was used to perform three rounds of screening to obtain the MDSCs targeting polypeptide DPPWLSW (abbreviated as F7, as shown in SEQ ID NO.1). The specific method is as follows:

[0048] (1) In vivo phage screening

[0049] First round of screening:

[0050] 1. Take one tumor-bearing mouse and inject 100 μl Ph.D.-7 into the tail vein TM Phage 7 peptide library (4*10 11 pfu). After 1 hour, 200 μl of 4% chloral hydrate was anesthetized, and 40 ml of PBS was perfused into the myocardium, and then the tumor tissue was collected.

[0051] 2. Cleavage of MDSCs cells: add 100 μl of 1% NP-40 cell lysate to the sorted MDSCs cells, mix well, and lyse on ice for 5 minutes.

[0052] 3. A single colony of ER2738 was inoculated into LB-Tet (LB-tetracycline) medium for overnight culture, and the culture was diluted 1:100 into one 25...

Embodiment 2

[0083] Embodiment 2, have the synthetic material of MDSCs targeting

[0084] This embodiment relates to a synthetic material with MDSCs targeting, which is obtained by linking a derivative polypeptide of MDSC molecule-specific targeting polypeptide with Mal-PEG2000-DSPE. When the sequence of the MDSCs molecule-specific targeting polypeptide is synthesized, GGGC is added to the C-terminus to obtain a derivative polypeptide whose sequence is DPPWLSWGGGC (as shown in SEQ ID NO.3); the free sulfhydryl group on the cysteine ​​of the derivative polypeptide To react with the maleimide group and connect to DSPE-2000-Maleimide (distearoylglyceroylphosphatidylethanolamine polyethylene glycol 2000 maleimide, the polyethylene glycol can also choose PEG5000), A synthetic material with MDSCs targeting is obtained; further, the MDSCs-specific targeting polypeptide can also be directly linked with DSPE-2000-Maleimide; another synthetic material with MDSCs targeting is obtained.

[0085] Th...

Embodiment 3

[0090] Example 3, Derivative polypeptides of MDSCs targeting polypeptides

[0091] 1. Binding experiment of MDSCs, Jurkat and polypeptide DPPWLSW-FITC (suspension cells)

[0092] 1) MDSCs, Jurkat cell counting, 1640 culture medium (10% fetal calf serum) to adjust the cell concentration to 2 × 10 6 pieces / ml. 24-well plate, 200 μl cell suspension per well.

[0093] 2) Under the dark condition, 20 μl of polypeptide DPPWLSW-FITC solution with different concentrations were added to each well, and the concentrations were respectively 1 mM, 500 μM, 50 μM, 5 μM and 0.5 μM. After mixing, 37°C, 5% CO 2 Incubate for 1 h in the dark.

[0094] 3) After the incubation, discard the cell culture medium containing the fluorescent polypeptide, add PBS+2% FBS buffer solution 400 μl / well, 300g, 10min, centrifuge and wash 3 times, thoroughly wash to remove free or non-specifically bound fluorescent polypeptide.

[0095] 4) Using a flow cytometer, count 10,000 cells under an excitation ligh...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
Login to View More

Abstract

The invention discloses a ligand polypeptide specifically combined with MDSCs (Myeloid-Derived Suppressor Cells) and a drug delivery system. The ligand polypeptide specifically combined with MDSCs comprises an amino acid sequence as shown in SEQ ID NO.1. The drug delivery system disclosed by the invention comprises the ligand polypeptide, a drug carrying system and at least one active or developing substance, wherein the drug carrying system is specifically lipidosome; the at least one active substance is any substance which is needed to be delivered to a special in-vivo position. The ligand polypeptide disclosed by the invention has good MDSCs-targeting effect, and can be combined with lipidosome to be used as a targeting drug carrier, so that a targeting drug delivery system for tumors is developed.

Description

technical field [0001] The invention relates to the technical field of protein polypeptides, in particular to a ligand polypeptide specifically combined with MDSCs and a drug delivery system. Background technique [0002] Tumor is one of the main causes affecting human health. Theoretically speaking, the immune system can recognize the tumor as the non-self of the body, thereby inhibiting the occurrence and development of the tumor, but in fact, the tumor host usually has low immunity and cannot produce effective anti-tumor immunity. In recent years, the tumor immunoediting hypothesis about the interaction between tumor development and the body's immune system has attracted people's attention. The hypothesis holds that tumor cells form a stable tumor immune tolerance pattern by reducing their own immunogenicity, down-regulating the expression of co-stimulatory molecules on the cell surface, releasing a large number of immunosuppressive factors, and recruiting a variety of i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K7/06A61K47/42A61K48/00A61K41/00A61K49/22A61K51/08A61K9/127A61P35/00
Inventor 徐宇虹司晓菲吴烈宜张金平陈晓龙
Owner SHANGHAI JIAO TONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com